Latest News from Allyx
December 10, 2025
Allyx Therapeutics Announces Successful Completion of Two Additional Studies of Lead Candidate ALX-001
October 14, 2024
Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
September 4, 2024
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
June 11, 2024
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
March 5, 2024
Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance
October 30, 2023
Allyx Therapeutics releases top-line Phase 1a data for ALX-001, demonstrating oral administration is safe and well-tolerated at all doses and achieves full brain receptor occupancy.
